登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：601089 证券简称：福元医药 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第三季度财务报表是否经审计 □是√否 审计师发表非标意见的事项 □适用 √不适用 一、主要财务数据 （一）主要会计数据和财务指标 单位：元 币种：人民币 ■ 注："本报告期"指本季度初至本季度末3个月期间，下同。 （二）非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项 ...

证券代码： 002437 证券简称：誉衡药业 哈尔滨誉衡药业股份有限公司投资者关系活动记录表 2025-010 | □ | 特定对象调研 □ 分析师会议 | | | | --- | --- | --- | --- | | □ | 媒体采访 √ | | 业绩说明会 | | 投资者关系活动 □ | 新闻发布会 路演活动 □ | | | | 类别 | | | | | □ | 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） 天风证券、东吴证券、信达证券、中金公司、中信建投、国盛证 | | | | | 券、招商证券、首创证券、中信证券、国泰海通、华福证券、国 | | | | | 泰君安资产管理股份有限公司、青骊投资管理（上海）有限公司、 | | | | 参与单位名称及 | 富安达基金管理有限公司、天治基金管理有限公司、长江证券（上 | | | | 人员姓名 | 海）资产管理有限公司、申万菱信基金管理有限公司、创金合信 | | | | | 基金管理有限公司、深圳市思加私募证券基金管理有限公司、和 | | | | | 谐健康保险股份有限公司、循远资产管理（上海）有限公司、中 | | | | | 国人保资 ...

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) announced that six of its products are expected to be selected in the 11th national centralized drug procurement, which could enhance market share and positively impact future operating performance [1] Group 1: Product Selection - The six products include: Fumaric Acid Lurasidone Tablets, Pravastatin Sodium Tablets, Silodosin Tablets, Alendronate Sodium Tablets, Agomelatine Tablets, and Dopamine Hydrazine Tablets [1] - If these products are selected and sales contracts are signed, it will contribute to an increase in market share for the company [1] Group 2: Financial Impact - The products that were not selected, such as Dapagliflozin Tablets, did not generate sales in 2024 and had sales of 2.9413 million yuan from January to September 2025, accounting for 0.1167% of the company's revenue during the same period [1] - The lack of selection for these products is not expected to have a significant impact on the company's production and operations [1]

人民财讯10月29日电，海正药业（600267）10月29日公告，公司及全资子公司瀚晖制药有限公司参加了 联合采购办公室组织的第十一批全国药品集中采购的投标工作。根据联采办于2025年10月28日在上海阳 光医药采购网发布的《全国药品集中采购拟中选结果公示》，公司及全资子公司瀚晖制药符合本次集中 采购范围的3个产品拟中标本次集中采购，分别为普伐他汀钠片、注射用丁二磺酸腺苷蛋氨酸、艾曲泊 帕乙醇胺片。 ...

每经头条（nbdtoutiao）——A股突破4000点！十年沉寂终迎爆发，科技主线重塑市场，"慢牛"新格局开 启！ （记者 曾健辉） 2024年1至12月份，海正药业的营业收入构成为：医药生产占比58.46%，药品销售占比39.29%，其他行 业占比1.94%，其他业务占比0.23%，CMO/CDMO/CRO业务占比0.08%。 截至发稿，海正药业市值为132亿元。 每经AI快讯，海正药业（SH 600267，收盘价：11.03元）10月29日晚间发布公告称，近日，浙江海正药 业股份有限公司及全资子公司瀚晖制药有限公司参加了联合采购办公室组织的第十一批全国药品集中采 购的投标工作。根据联采办于2025年10月28日在上海阳光医药采购网发布的《全国药品集中采购拟中选 结果公示》，公司及全资子公司瀚晖制药符合本次集中采购范围的3个产品拟中标本次集中采购。普伐 他汀钠片，2025年1-6月销售收入5420万元。注射用丁二磺酸腺苷蛋氨酸，2025年1-6月销售收入8896万 元。艾曲泊帕乙醇胺片，2025年1-6月销售收入74万元。 ...

Investment Rating - The investment rating for the company is "Add" [1] Core Views - The company has shown continuous improvement in operational efficiency and has good growth potential in its CSO (Contract Sales Organization) business [4] - Key products have maintained stable growth, with significant sales increases in certain categories due to marketing reforms and favorable policy changes [6] - The company has a strong foundation in its CSO business, with ongoing collaborations expected to contribute to revenue growth [6] - Earnings forecasts indicate a slight decline in revenue for 2025, followed by a recovery and growth in subsequent years, with net profit expected to grow steadily [5][6] Financial Summary - The latest closing price is 3.39 CNY, with a one-year high of 4.08 CNY and a low of 1.80 CNY [3] - The current P/E ratio is 31.43, and the P/B ratio is 3.72 [3] - Total shares outstanding are 2.246 billion, with a total market capitalization of 7.613 billion CNY [3] - Revenue for 2024 is projected at 24.41 billion CNY, with a slight decline in 2025 to 24.37 billion CNY, followed by growth to 27.51 billion CNY in 2026 and 30.80 billion CNY in 2027 [5] - Net profit for 2024 is estimated at 2.33 billion CNY, increasing to 2.56 billion CNY in 2025, 2.91 billion CNY in 2026, and 3.28 billion CNY in 2027 [5] - The company’s sales expense ratio has decreased by 8.30 percentage points year-on-year, and management expenses have decreased by 21.58% [6]

Group 1: Financial Performance - The company's revenue for the first half of 2025 reached 1.567 billion CNY, a 23.87% increase from 1.265 billion CNY in the same period last year [3] - The net profit attributable to shareholders was 149.51 million CNY, a significant increase of 180.96% year-on-year [3] - The gross profit margin improved to 38%, up three percentage points from the previous year [3] Group 2: Business Segment Performance - Revenue from the generic drug raw materials and intermediates business was 1.131 billion CNY, with non-sartan raw materials showing continuous growth [3] - The CDMO (Contract Development and Manufacturing Organization) business generated 251.63 million CNY, reflecting a 44.33% year-on-year growth [8] - The formulation business achieved sales revenue of 847.2 million CNY, a year-on-year increase of 84.72%, with sales volume surpassing 500 million tablets, a 71% increase [3] Group 3: Market Strategy and Expansion - The company successfully participated in national and provincial alliance procurement projects, significantly enhancing terminal coverage [4] - A multi-channel sales network has been established, including medical, retail e-commerce, and internet centers, contributing to rapid growth across all business segments [4] - The company has received 65 drug production approvals covering 40 varieties, enhancing product structure and market opportunities [3] Group 4: Future Outlook and Challenges - The company anticipates further improvements in gross margins due to ongoing cost reduction and efficiency enhancement measures [5] - The sartan product line faced price pressure but maintained stable sales volume, with a focus on optimizing production processes [6] - The company plans to enhance cash flow management to address a net cash flow deficit of 17.77 million CNY, primarily due to increased accounts receivable [12]

Core Viewpoint - Yuheng Pharmaceutical has demonstrated outstanding performance in a relatively sluggish pharmaceutical industry, achieving significant growth in core products and cost reduction efforts, with a notable increase in net profit and cash flow in 2024 and Q1 2025 [1][2][7] Financial Performance - In 2024, the company's net profit attributable to shareholders increased by 93.43% year-on-year, reaching 233 million yuan, while the net profit excluding non-recurring items surged by 243.42% to 183 million yuan [1] - For Q1 2025, the net profit attributable to shareholders and net profit excluding non-recurring items grew by 15.24% and 54.74% year-on-year, amounting to approximately 60.25 million yuan and 49.73 million yuan, respectively [1] - The operating cash flow increased by 49.88% year-on-year to 411 million yuan, and the weighted average return on equity rose to 12.89%, up 5.63 percentage points [2] - The basic earnings per share increased by 93.60% to 0.1059 yuan/share in 2024, with a further 16.60% growth in Q1 2025, reaching 0.0274 yuan/share [2] Asset Quality Improvement - By the end of 2024, the net assets attributable to shareholders grew by 17.39% year-on-year to approximately 1.951 billion yuan, while the debt-to-asset ratio decreased by 15.58 percentage points to 30.17%, the lowest level in a decade [2] - The company’s operational efficiency improved, with current asset turnover increasing from 1.77 times to 2.40 times, and total asset turnover rising from 0.73 times to 0.82 times [3] Sales Efficiency and Cost Management - In 2024, the company enhanced sales efficiency through organizational adjustments and process management, resulting in a 25.82% decrease in sales expenses, with the sales expense ratio falling to 32.48% [3] - Management expenses and financial costs also saw significant reductions, with management expenses down 18.29% and financial expenses down 103.41% in 2024 [3] Product Development and Innovation - The company has maintained a "Product First" strategy, expanding its product line from orthopedics to major therapeutic areas such as cardiovascular and cerebrovascular diseases, with several core products experiencing rapid sales growth [4] - In 2024, sales of the exclusive traditional Chinese medicine product An Nao Wan/Pian grew over 90%, while the injection of multiple vitamins maintained an 80% market share with a 40% sales increase [4] - The company has a robust pipeline of over 20 projects, with several products receiving drug approval numbers and others undergoing consistency evaluations [6] Strategic Partnerships - Yuheng Pharmaceutical has strengthened its collaboration with the global pharmaceutical company Daiichi Sankyo, signing promotional agreements for new products, which are expected to contribute positively to the company's performance [5][6] Market Confidence and Shareholder Engagement - The company launched an equity incentive plan covering over 100 key personnel and implemented a share repurchase plan, reflecting confidence in its future development [6] - Major shareholders have collectively increased their holdings by nearly 30 million shares, indicating strong market confidence in the company's long-term value proposition [6][7]